ClinicalTrials.gg
CompletedNCT07518459Updated Jun 22, 2026

A Study of Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]AZD4144

A Phase 1 interventional study of [14C]AZD4144 Solution for Infusion and [14C]AZD4144 Oral Solution in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
30 Years to 65 Years
Sex
All
01

Study summary

This study in healthy volunteers aims to explore blood levels and side effects of the test medicine, and look at how it is broken down when injected into a vein or given as a liquid by mouth. The test medicine will be radiolabeled with a small amount of carbon-14 so it can be tracked in the body.

This study will take place at one site in Nottingham, United Kingdom, and will enroll 2 groups of 8 healthy men aged 30-65 years.

Read the detailed description

This study in healthy volunteers aims to explore blood levels and side effects of the test medicine, and look at how it is broken down when injected into a vein or given as a liquid by mouth. The test medicine will be radiolabelled with a small amount of carbon-14 so it can be tracked in the body.

This study will take place at one site in Nottingham, United Kingdom.

It is planned to enroll 2 groups of 8 healthy men aged 30-65 years.

Each group will take part in 1 treatment period and receive a single dose of radiolabelled test medicine, either by injection into a vein or as a liquid by mouth. They'll stay in the clinic for up to 10 nights, attend 2 outpatient visits, and take up to 7 weeks to finish the study.

Blood and urine samples will be collected to do safety tests. Blood, urine and faecal samples will be collected to measure the amount of test medicine and its breakdown products.

02

Conditions studied

  • Healthy Participants

Keywords

  • Healthy participants
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males aged 30 to 65 years inclusive
  • of 18.0 to 32.0 kg/m2 inclusive
  • Regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day)

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder
  • History or presence of clinically significant cardiovascular, renal, respiratory, gastrointestinal disease, or neurological or psychiatric disorder
  • Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first dosing day
  • Acute diarrhoea or constipation within 7 days of the first dosing day
  • Participants who do not have suitable veins for multiple venepunctures/cannulation
  • Clinically significant abnormal clinical chemistry, haematology, coagulation or urinalysis
  • Any clinically significant abnormal findings in vital signs
  • Any clinically significant abnormalities on 12-lead
  • Evidence of renal impairment
  • Participants who have received any IMP in the last 90 days prior to the first dosing day
  • Participants who have previously received AZD4144
  • Radiation exposure exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years, occupationally exposed worker, or have been administered IMP in a radiolabelled ADME study in the last 12 months.
  • Blood or plasma donation, or loss of more than 400 mL blood during the 3 months prior to the study.
  • Use of any prescribed or non-prescribed medication including antacids, gastric pH modifying agents, analgesics, herbal remedies, vitamins and minerals within 2 weeks of the first dosing day
  • Use of drugs or herbal medications with enzyme-inducing properties such as St John's Wort or CYP3A4 inhibiting properties within 3 weeks of the first dosing day
  • Current smokers or known or suspected history of alcohol or drug abuse
  • Excessive intake of caffeine-containing drinks or food
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Regimen A

    Participants in Cohort 1 will receive a single intravenous injection of \[14C\]AZD4144 Solution for Infusion

    Drug: [14C]AZD4144 Solution for Infusion

  • Experimental
    Regimen B

    Participants in Cohort 2 will receive a single oral dose of \[14C\]AZD4144 Oral Solution

    Drug: [14C]AZD4144 Oral Solution

Interventions

06

What researchers measure

Primary outcomes

  1. Amount of AZD4144 excreted (Ae)

    Mass balance recovery, rates and routes of elimination of total radioactivity of \[14C\]AZD4144 in urine, faecal and all excreta

    Time frame: Urine and faecal samples collected from pre-dose until up to 216 hours post-dose

  2. Amount of AZD4144 excreted expressed as a percentage of the radioactive dose administered (Fe)

    Mass balance recovery, rates and routes of elimination of total radioactivity of \[14C\]AZD4144 in urine, faeces and all excreta

    Time frame: Urine and faecal samples collected from pre-dose until up to 216 hours post-dose

  3. Cumulative amount of AZD4144 excreted (CumAe)

    Mass balance recovery, rates and routes of elimination of total radioactivity of \[14C\]AZD4144 in urine, faecal and all excreta

    Time frame: Urine and faecal samples collected from pre-dose until up to 216 hours post-dose

  4. Cumulative amount of AZD4144 excreted expressed as a percentage of the radioactive dose administered (CumFe)

    Mass balance recovery, rates and routes of elimination of total radioactivity of \[14C\]AZD4144 in urine, faecal and all excreta

    Time frame: Urine and faecal samples collected from pre-dose until up to 216 hours post-dose

  5. Area under the curve (AUC) of circulating plasma total radioactivity (TR) accounting for 10% or more of the dose

    Identification of the chemical structure of each metabolite accounting for more than 10% by AUC of circulating total radioactivity

    Time frame: Plasma, urine and faecal samples from pre-dose until up to 216 hours post-dose

  6. 80% or more of the radioactivity recovered in excreta

    Identification of greater than 80% of the radioactivity recovered in the urine and/or faeces

    Time frame: Plasma, urine and faecal samples from pre-dose until up to 216 hours post-dose

Secondary outcomes

  1. Time of maximum observed concentration (tmax) for AZD4144 and total radioactivity

    The PK of AZD4144 in plasma and urine, and total radioactivity in plasma and whole blood

    Time frame: Plasma, urine and whole blood samples collected from pre-dose until up to 168 hours post-dose

  2. Maximum observed concentration (Cmax) for AZD4144 and total radioactivity

    The PK of AZD4144 in plasma and urine, and total radioactivity in plasma and whole blood

    Time frame: Plasma, urine and whole blood samples collected from pre-dose until up to 168 hours post-dose

  3. Area under the curve from time 0 to the time of last measurable concentration (AUC0-t) for AZD4144 and total radioactivity

    The PK of AZD4144 in plasma and urine, and total radioactivity in plasma and whole blood

    Time frame: Plasma, urine and whole blood samples collected from pre-dose until up to 168 hours post-dose

  4. Area under the curve from time 0 extrapolated to infinity (AUC0-inf) for AZD4144 and total radioactivity

    The PK of AZD4144 in plasma and urine, and total radioactivity in plasma and whole blood

    Time frame: Plasma, urine and whole blood samples collected from pre-dose until up to 168 hours post-dose

  5. Area under the curve from time of the last measurable concentration to infinity as a percentage of the area under the curve extrapolated to infinity (AUCextrap) for AZD4144 and total radioactivity

    The PK of AZD4144 in plasma and urine, and total radioactivity in plasma and whole blood

    Time frame: Plasma, urine and whole blood samples collected from pre-dose until up to 168 hours post-dose

  6. Terminal elimination half-life (T1/2) for AZD4144 and total radioactivity

    The PK of AZD4144 in plasma and urine, and total radioactivity in plasma and whole blood

    Time frame: Plasma, urine and whole blood samples collected from pre-dose until up to 168 hours post-dose

  7. Apparent volume of distribution at steady state after a single IV administration (Vss) for AZD4144 and total radioactivity

    The PK of AZD4144 in plasma and urine, and total radioactivity in plasma and whole blood

    Time frame: Plasma, urine and whole blood samples collected from pre-dose until up to 168 hours post-dose

  8. Total body clearance calculated after a single IV administration (CL) for AZD4144 and total radioactivity

    The PK of AZD4144 in plasma and urine, and total radioactivity in plasma and whole blood

    Time frame: Plasma, urine and whole blood samples collected from pre-dose until up to 168 hours post-dose

  9. Renal clearance calculated using plasma AUC (CLR) for AZD4144 and total radioactivity

    The PK of AZD4144 in plasma and urine, and total radioactivity in plasma and whole blood

    Time frame: Plasma, urine and whole blood samples collected from pre-dose until up to 168 hours post-dose

  10. Whole blood:plasma concentration ratios

    Whole blood:plasma concentration ratios for total radioactivity

    Time frame: Whole blood and plasma samples collected from pre-dose until 168 hours post-dose

  11. Absolute bioavailability

    Absolute bioavailability (F) of AZD4144 based on AUC0-inf

    Time frame: Plasma samples collected from pre-dose until 168 hours post-dose

07

Study locations

1 site
  • Research Site
    Ruddington, NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual participant-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2026 to primary completion in May 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Apr 8, 2026
StartActual
Feb 11, 2026
Primary completionActual
May 26, 2026
CompletionActual
May 26, 2026
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07518459
Lead sponsor
AstraZeneca
Collaborators
Quotient Sciences
Responsible party
Sponsor
First posted
Apr 8, 2026
Start date
Feb 11, 2026
Primary completion
May 26, 2026
Completion
May 26, 2026
Last update
Jun 22, 2026

Study contacts

Sharan Sidhu, MBChB, BAO
principal investigator · Quotient Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD4144

Start the discussion